Market Summary
USD73.27-0.83
Market Closed-1.12%
GILD Alerts
GILD Stock Price
GILD RSI Chart
GILD Valuation
GILD Price/Sales (Trailing)
GILD Profitability
GILD Fundamentals
GILD Revenue
GILD Earnings
Price Action
52 Week Range
62.4888.45
(Low)(High)
Last 7 days
-1.0%
Last 30 days
-3.3%
Last 90 days
-3.4%
Trailing 12 Months
22.3%
GILD Financial Health
GILD Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for GILD
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-12 | Parsey Merdad | sold | -115,562 | 76.99 | -1,501 | chief medical officer |
2023-09-10 | Patterson Sandra | acquired | - | - | 519 | svp, controllership |
2023-09-10 | Parsey Merdad | sold (taxes) | -97,128 | 76.00 | -1,278 | chief medical officer |
2023-09-10 | Mercier Johanna | sold (taxes) | -95,456 | 76.00 | -1,256 | chief commercial officer |
2023-09-10 | O'Day Daniel Patrick | acquired | - | - | 7,348 | chairman & ceo |
2023-09-10 | Patterson Sandra | sold (taxes) | -11,324 | 76.00 | -149 | svp, controllership |
2023-09-10 | Dickinson Andrew D | acquired | - | - | 2,619 | chief financial officer |
2023-09-10 | Mercier Johanna | acquired | - | - | 2,730 | chief commercial officer |
2023-09-10 | O'Day Daniel Patrick | sold (taxes) | -255,816 | 76.00 | -3,366 | chairman & ceo |
2023-09-10 | Parsey Merdad | acquired | - | - | 2,779 | chief medical officer |
Which funds bought or sold GILD recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-10-02 | PARK NATIONAL CORP /OH/ | added | 22.51 | 49,240 | 306,654 | 0.01% |
2023-09-26 | M Holdings Securities, Inc. | sold off | -100 | -726,000 | - | -% |
2023-09-26 | BROOKFIELD Corp /ON/ | reduced | -92.45 | -2,694,740 | 203,234 | -% |
2023-09-21 | Baystate Wealth Management LLC | added | 17.83 | 2,775 | 32,616 | -% |
2023-09-21 | Jefferies Group LLC | new | - | 2,313,740 | 2,313,740 | 0.02% |
2023-09-20 | Mondrian Investment Partners LTD | unchanged | - | -17,853 | 233,214 | -% |
2023-09-20 | BARCLAYS PLC | added | 47.07 | 137,216,000 | 511,970,000 | 0.32% |
2023-09-14 | IMS Capital Management | unchanged | - | -28,987 | 378,645 | 0.21% |
2023-09-12 | Farther Finance Advisors, LLC | added | 3.14 | -22,010 | 503,190 | 0.11% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | added | 13.72 | 14,280 | 267,587 | 0.08% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
GILD Alerts
Schedule 13G FIlings of Gilead Sciences
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 13, 2023 | capital research global investors | 4.4% | 54,602,952 | SC 13G/A | |
| Feb 13, 2023 | capital world investors | 5.5% | 68,900,998 | SC 13G | |
| Feb 09, 2023 | vanguard group inc | 8.93% | 112,038,324 | SC 13G/A | |
| Jan 31, 2023 | blackrock inc. | 10.5% | 131,555,769 | SC 13G/A | |
| Jul 08, 2022 | blackrock inc. | 10.1% | 126,932,693 | SC 13G | |
| Feb 11, 2022 | capital research global investors | 8.5% | 107,156,981 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 8.43% | 105,803,799 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 9.5% | 118,961,206 | SC 13G/A | |
| Feb 16, 2021 | capital research global investors | 9.7% | 121,672,399 | SC 13G/A | |
| Feb 16, 2021 | capital research global investors | 9.7% | 121,672,399 | SC 13G/A |
Recent SEC filings of Gilead Sciences
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 29, 2023 | 4 | Insider Trading | |
| Sep 14, 2023 | 8-K | Current Report | |
| Sep 13, 2023 | 4 | Insider Trading | |
| Sep 12, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 11, 2023 | 4 | Insider Trading | |
| Sep 11, 2023 | 4 | Insider Trading | |
| Sep 11, 2023 | 4 | Insider Trading | |
| Sep 11, 2023 | 4 | Insider Trading | |
| Sep 11, 2023 | 4 | Insider Trading | |
| Sep 11, 2023 | 424B5 | Prospectus Filed |
GILD Fair Value
Loading...
Peers (Alternatives to Gilead Sciences)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 142.4B | 26.6B | 3.74% | 20.01% | 17.85 | 5.36 | 0.75% | 21.34% |
GILD | 92.4B | 27.4B | -3.33% | 22.27% | 16.85 | 3.37 | -0.48% | 32.56% |
MRNA | 39.4B | 10.7B | -8.22% | -12.63% | 32.61 | 3.69 | -53.67% | -91.41% |
BIIB | 36.6B | 10.0B | -5.36% | -5.30% | 13.73 | 3.67 | -6.23% | 29.40% |
| MID-CAP | ||||||||
NBIX | 10.9B | 1.7B | 1.05% | 5.25% | 61.85 | 6.52 | 29.01% | 1345.90% |
BBIO | 4.1B | - | -16.91% | 155.63% | -7.02 | 48.33 | 54.84% | -12.96% |
DNLI | 2.7B | - | -15.10% | -35.52% | -21.18 | 37.44 | 122.90% | 54.78% |
BEAM | 1.7B | 80.2M | -8.35% | -54.87% | -5.12 | 20.91 | 42.17% | -39.82% |
| SMALL-CAP | ||||||||
RCUS | 1.3B | 121.2M | -18.44% | -33.91% | -4.48 | 10.62 | -70.36% | -531.73% |
REPL | 931.2M | 15.3M | -19.93% | -8.57% | -5.13 | 60.82 | 1090.59% | -36.57% |
NVAX | 668.6M | 1.6B | -13.64% | -61.04% | -1.14 | 0.42 | 23.74% | 60.24% |
FATE | 189.2M | - | -31.67% | -91.43% | -0.89 | 1.38 | 116.83% | 16.61% |
VXRT | 113.0M | 2.1M | -10.53% | -65.89% | -1.12 | 55 | 487.70% | -8.66% |
SGMO | 104.6M | - | -38.94% | -87.76% | -0.53 | 0.43 | 113.96% | -15.19% |
IBIO | 6.3M | - | 5.48% | -92.77% | -0.08 | 3.21 | - | -129.46% |
Gilead Sciences News
Returns for GILD
Cumulative Returns on GILD
4.4%
10-Year Cumulative Returns
2.7%
7-Year Cumulative Returns
2.4%
5-Year Cumulative Returns
9.9%
3-Year Cumulative Returns
Risks for GILD
What is the probability of a big loss on GILD?
41.9%
Probability that Gilead Sciences stock will be more than 20% underwater in next one year
0%
Probability that Gilead Sciences stock will be more than 30% underwater in next one year.
0%
Probability that Gilead Sciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does GILD drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Gilead Sciences was unfortunately bought at previous high price.
Drawdowns
Financials for Gilead Sciences
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 1.3% | 27,382 | 27,043 | 27,281 | 27,136 | 27,515 | 27,472 | 27,305 | 27,482 | 26,638 | 25,564 | 24,689 | 23,147 | 22,174 | 22,716 | 22,449 | 22,365 | 22,357 | 22,320 | 22,127 | 22,281 | 23,197 |
| Costs and Expenses | 3.9% | 18,908 | 18,205 | 19,951 | 21,133 | 20,507 | 20,247 | 17,387 | 15,853 | 16,850 | 21,005 | 20,618 | 20,634 | 23,135 | 18,264 | 18,162 | 18,027 | 13,923 | 14,036 | 13,927 | 12,934 | 12,661 |
| S&GA Expenses | 8.3% | 6,401 | 5,909 | 5,673 | 5,303 | 5,280 | 5,274 | 5,246 | 5,326 | 5,242 | 5,130 | 5,151 | 4,625 | 4,571 | 4,427 | 4,381 | 4,308 | 4,204 | 4,089 | 4,056 | 4,177 | 4,108 |
| R&D Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9,150 | 9,106 | 9,157 | 5,106 | 5,138 | 5,018 | 3,290 | 3,140 |
| EBITDA | -100.0% | - | 8,530 | 7,072 | 5,819 | 6,848 | 7,175 | 9,608 | 10,681 | 8,045 | 2,930 | 2,653 | 2,716 | 404 | 5,795 | 6,155 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.32* | 0.26* | 0.21* | 0.25* | 0.26* | 0.35* | 0.39* | 0.30* | 0.11* | 0.11* | 0.12* | 0.02* | 0.26* | 0.27* | - | - | - | - | - | - |
| Interest Expenses | -1.3% | 915 | 927 | 935 | 947 | 968 | 982 | 1,001 | 1,030 | 1,016 | 1,000 | 984 | 960 | 974 | 982 | 995 | 1,009 | 1,023 | 1,041 | 1,077 | 1,117 | 1,144 |
| Earnings Before Taxes | 1.2% | 7,351 | 7,266 | 5,814 | 4,542 | 5,548 | 5,862 | 8,278 | 9,333 | 6,720 | 1,930 | 1,669 | 1,756 | -570 | 4,813 | 5,160 | 4,275 | 8,440 | 8,116 | 7,799 | 8,909 | 9,916 |
| EBT Margin | -100.0% | - | 0.27* | 0.21* | 0.17* | 0.20* | 0.21* | 0.30* | 0.34* | 0.25* | 0.08* | 0.07* | 0.08* | -0.03* | 0.21* | 0.23* | - | - | - | - | - | - |
| Net Income | -1.8% | 5,484 | 5,583 | 4,592 | 3,334 | 4,137 | 4,515 | 6,225 | 7,394 | 5,162 | 301 | 123 | 1,268 | -257 | 4,962 | 5,386 | 2,693 | 5,955 | 5,892 | 5,455 | 1,587 | 2,208 |
| Net Income Margin | -100.0% | - | 0.21* | 0.17* | 0.12* | 0.15* | 0.16* | 0.23* | 0.27* | 0.19* | 0.01* | 0.00* | 0.05* | -0.01* | 0.22* | 0.24* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 8,386 | 8,344 | 9,007 | 9,415 | 9,953 | 10,805 | 9,491 | 8,472 | 8,698 | 7,518 | 8,160 | 8,764 | 8,244 | 8,319 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 0.7% | 62,337 | 61,876 | 63,171 | 62,557 | 62,870 | 63,080 | 67,952 | 67,098 | 67,984 | 67,492 | 68,407 | 60,878 | 55,934 | 59,741 | 61,627 | 59,146 | 63,210 | 62,837 | 63,675 | 64,305 | 65,355 |
| Current Assets | 6.2% | 14,287 | 13,456 | 14,443 | 13,554 | 13,175 | 12,629 | 14,772 | 13,991 | 13,925 | 13,278 | 15,996 | 30,926 | 24,643 | 26,950 | 30,296 | 28,361 | 33,727 | 34,024 | 35,836 | 34,918 | 32,728 |
| Cash Equivalents | 15.6% | 5,704 | 4,936 | 5,412 | 4,699 | 4,739 | 4,296 | 5,338 | 4,362 | 4,893 | 4,065 | 5,997 | 12,886 | 6,746 | 10,051 | 11,631 | 9,474 | 11,240 | 16,927 | 17,940 | 14,569 | 13,234 |
| Inventory | 3.6% | 1,633 | 1,576 | 1,507 | 1,463 | 1,494 | 1,482 | 1,618 | 1,676 | 1,772 | 1,779 | 1,683 | 1,008 | 1,052 | 986 | 922 | 882 | 884 | 898 | 814 | 816 | 859 |
| Net PPE | 1.1% | 5,540 | 5,479 | 5,475 | 5,349 | 5,299 | 5,253 | 5,121 | 5,037 | 4,996 | 4,990 | 4,967 | 4,810 | 4,653 | 4,564 | 4,502 | 4,377 | 4,249 | 4,116 | 4,006 | 3,791 | 3,659 |
| Goodwill | 0% | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,332 | 8,332 | 8,334 | 8,334 | 8,108 | 4,117 | 4,117 | 4,117 | 4,117 | 4,117 | 4,117 | 4,117 | 4,117 | 4,117 | 4,124 |
| Current Liabilities | 32.6% | 13,964 | 10,528 | 11,237 | 10,423 | 9,220 | 8,558 | 11,610 | 10,245 | 10,214 | 9,705 | 11,397 | 9,509 | 10,564 | 8,879 | 9,759 | 9,567 | 8,961 | 9,397 | 10,605 | 10,116 | 10,912 |
| LT Debt, Non Current | -7.6% | 21,209 | 22,956 | 22,957 | 22,953 | 25,195 | 25,183 | 25,179 | 25,175 | 27,914 | 27,907 | 28,645 | 27,792 | 21,103 | 22,098 | 22,094 | 22,090 | 24,084 | 24,080 | 24,574 | 24,570 | 26,062 |
| Shareholder's Equity | 1.0% | 21,158 | 20,939 | 21,240 | 21,081 | 20,215 | 19,915 | 21,064 | 21,471 | 19,710 | 18,964 | 18,221 | 17,471 | 18,142 | 22,179 | 22,650 | 20,736 | 22,751 | 22,091 | 21,534 | 23,007 | 21,734 |
| Retained Earnings | -0.6% | 15,138 | 15,223 | 15,687 | 15,756 | 15,117 | 14,986 | 16,324 | 16,903 | 15,392 | 14,821 | 14,381 | 13,709 | 14,445 | 18,709 | 19,388 | 17,616 | 19,829 | 19,326 | 19,024 | 20,706 | 19,825 |
| Additional Paid-In Capital | 3.7% | 6,008 | 5,793 | 5,550 | 5,226 | 5,031 | 4,867 | 4,661 | 4,492 | 4,271 | 4,092 | 3,880 | 3,712 | 3,511 | 3,311 | 3,051 | 2,870 | 2,684 | 2,494 | 2,282 | 2,118 | 1,844 |
| Shares Outstanding | -0.1% | 1,247 | 1,248 | 1,247 | 1,254 | 1,256 | 1,255 | 1,254 | 1,256 | 1,255 | 1,256 | 1,254 | 1,255 | 1,255 | 1,262 | 1,266 | 1,267 | 1,270 | 1,276 | 1,282 | 1,296 | 1,298 |
| Minority Interest | -10.3% | -64.00 | -58.00 | -31.00 | -24.00 | -21.00 | -12.00 | -5.00 | 1.00 | 7.00 | 12.00 | 19.00 | 26.00 | 115 | 112 | 125 | 132 | 135 | 140 | 147 | 146 | 62.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 6.0% | 9,512 | 8,976 | 9,072 | 9,710 | 10,100 | 10,614 | 11,384 | 10,095 | 9,092 | 9,342 | 8,168 | 8,832 | 9,227 | 9,003 | 9,144 | 8,909 | 8,476 | 7,707 | 8,400 | 8,808 | 9,290 |
| Share Based Compensation | 4.9% | 705 | 672 | 637 | 622 | 625 | 626 | 635 | 637 | 639 | 641 | 643 | 639 | 628 | 634 | 636 | 654 | 690 | 768 | 845 | 1,004 | 919 |
| Cashflow From Investing | -7.9% | -2,397 | -2,222 | -2,466 | -2,369 | -1,890 | -2,159 | -3,131 | -11,830 | -11,867 | -16,313 | -14,615 | -5,207 | -6,777 | -7,917 | -7,817 | -5,513 | -1,647 | 9,757 | 14,355 | 1,604 | -2,535 |
| Cashflow From Financing | -1.6% | -6,179 | -6,081 | -6,469 | -6,857 | -8,266 | -8,194 | -8,877 | -6,804 | 847 | 904 | 770 | -257 | -6,896 | -7,879 | -7,634 | -8,408 | -8,794 | -8,089 | -12,318 | -7,301 | -2,230 |
| Dividend Payments | 0.6% | 3,757 | 3,733 | 3,709 | 3,688 | 3,659 | 3,633 | 3,605 | 3,569 | 3,530 | 3,492 | 3,449 | 3,392 | 3,335 | 3,279 | 3,222 | 3,157 | 3,095 | 3,035 | 2,971 | 2,917 | 2,857 |
| Buy Backs | 5.4% | 1,570 | 1,490 | 1,396 | 699 | 654 | 633 | 546 | 541 | 596 | 609 | 1,583 | 1,733 | 1,747 | 2,278 | 1,749 | 2,641 | 2,876 | 2,742 | 2,900 | 2,091 | 1,757 |
GILD Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues: | ||||
| Total revenues | $ 6,599 | $ 6,260 | $ 12,951 | $ 12,850 |
| Costs and expenses: | ||||
| Cost of goods sold | 1,442 | 1,442 | 2,843 | 2,866 |
| Research and development expenses | 1,407 | 1,102 | 2,854 | 2,280 |
| Acquired in-process research and development expenses | 236 | 330 | 717 | 338 |
| In-process research and development impairment | 0 | 0 | 0 | 2,700 |
| Selling, general and administrative expenses | 1,849 | 1,357 | 3,168 | 2,440 |
| Total costs and expenses | 4,934 | 4,231 | 9,581 | 10,624 |
| Operating income | 1,665 | 2,029 | 3,370 | 2,226 |
| Interest expense | (230) | (242) | (459) | (480) |
| Other income (expense), net | 152 | (284) | (22) | (395) |
| Income before income taxes | 1,588 | 1,503 | 2,888 | 1,351 |
| Income tax expense | (549) | (368) | (865) | (204) |
| Net income | 1,039 | 1,135 | 2,024 | 1,147 |
| Net loss attributable to noncontrolling interest | 6 | 9 | 32 | 16 |
| Net income attributable to Gilead | $ 1,045 | $ 1,144 | $ 2,055 | $ 1,163 |
| Basic earnings per share attributable to Gilead (in dollars per share) | $ 0.84 | $ 0.91 | $ 1.65 | $ 0.93 |
| Shares used in basic earnings per share attributable to Gilead calculation (in shares) | 1,249 | 1,256 | 1,249 | 1,255 |
| Diluted earnings per share attributable to Gilead (in dollars per share) | $ 0.83 | $ 0.91 | $ 1.63 | $ 0.92 |
| Shares used in diluted earnings per share attributable to Gilead calculation (in shares) | 1,258 | 1,260 | 1,260 | 1,261 |
| Product sales | ||||
| Revenues: | ||||
| Total revenues | $ 6,564 | $ 6,138 | $ 12,870 | $ 12,672 |
| Royalty, contract and other revenues | ||||
| Revenues: | ||||
| Total revenues | $ 35 | $ 122 | $ 81 | $ 178 |
GILD Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 5,704 | $ 5,412 |
| Short-term marketable debt securities | 963 | 973 |
| Accounts receivable, net | 4,229 | 4,777 |
| Inventories | 1,633 | 1,507 |
| Prepaid and other current assets | 1,757 | 1,774 |
| Total current assets | 14,287 | 14,443 |
| Property, plant and equipment, net | 5,540 | 5,475 |
| Long-term marketable debt securities | 1,334 | 1,245 |
| Intangible assets, net | 27,750 | 28,894 |
| Goodwill | 8,314 | 8,314 |
| Other long-term assets | 5,113 | 4,800 |
| Total assets | 62,337 | 63,171 |
| Current liabilities: | ||
| Accounts payable | 622 | 905 |
| Accrued rebates | 3,494 | 3,479 |
| Other current liabilities | 5,810 | 4,580 |
| Current portion of long-term debt and other obligations, net | 4,037 | 2,273 |
| Total current liabilities | 13,964 | 11,237 |
| Long-term debt, net | 21,209 | 22,957 |
| Long-term income taxes payable | 2,610 | 3,916 |
| Deferred tax liability | 2,106 | 2,673 |
| Other long-term obligations | 1,354 | 1,179 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding | 0 | 0 |
| Common stock, par value $0.001 per share; 5,600 shares authorized; 1,247 shares issued and outstanding | 1 | 1 |
| Additional paid-in capital | 6,008 | 5,550 |
| Accumulated other comprehensive income | 10 | 2 |
| Retained earnings | 15,138 | 15,687 |
| Total Gilead stockholders’ equity | 21,158 | 21,240 |
| Noncontrolling interest | (64) | (31) |
| Total stockholders’ equity | 21,094 | 21,209 |
| Total liabilities and stockholders’ equity | $ 62,337 | $ 63,171 |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.